Cargando…

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Renin–angiotensin–aldosterone system (RAAS) inhibitors are the key medications for patients with heart failure and chronic kidney disease. Multiple randomized controlled trials have demonstrated their benefits in an outpatient setting for the treatment of chronic heart failure. Additional advantages...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singhania, Namrata, Bansal, Saurabh, Mohandas, Shreya, Nimmatoori, Divya P, Ejaz, Abutaleb A, Singhania, Girish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673621/ https://www.ncbi.nlm.nih.gov/pubmed/33240389 http://dx.doi.org/10.7573/dic.2020-7-3

Ejemplares similares

Current Overview on Hypercoagulability in COVID-19
por: Singhania, Namrata, et al.
Publicado: (2020)

Severe nonbacterial preseptal cellulitis from adenovirus detected via pooled meta‐genomic testing
por: Bansal, Saurabh, et al.
Publicado: (2020)

If You Go Up, You May Fall: A Rare Case of Rapidly Progressing Multifocal High-Altitude Vascular Thrombosis
por: Nimmatoori, Divya Pramod, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

An Atypical Presentation of Novel Coronavirus Disease 2019 (COVID-19)
por: Singhania, Namrata, et al.
Publicado: (2020)

Acute interstitial nephritis with only three doses of pantoprazole
por: Samal, Subhankar, et al.
Publicado: (2020)

Recurrent arteriovenous graft thrombosis in COVID‐19 positive patient
por: Singh, Anil Kumar, et al.
Publicado: (2021)

The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease
por: Andersen, Stine, et al.
Publicado: (2016)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022)

Membranous nephropathy associated with profound hypothyroidism
por: Singhania, Girish, et al.
Publicado: (2019)

Independent regulation of renin–angiotensin–aldosterone system in the kidney
por: Nishiyama, Akira, et al.
Publicado: (2018)

Office orthostatic blood pressure measurements and ambulatory blood pressure monitoring in the prediction of autonomic dysfunction
por: Alquadan, Kawther F., et al.
Publicado: (2017)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Rosano, Giuseppe MC, et al.
Publicado: (2019)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

Anaemia in Heart Failure Patients, Associated with Angiotensin – Renin – Aldosterone System Altering Medications
por: Jonaitienė, Neda, et al.
Publicado: (2021)

Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart Failure
por: Amatruda, Jonathan G., et al.
Publicado: (2022)

The effect of taurine supplementation on the renin–angiotensin–aldosterone system of dogs with congestive heart failure
por: Brethel, Sara, et al.
Publicado: (2023)

Old Era Continues in Modern World: A Case Report of Scurvy Induced Myopathy in Patient with Chronic Alcoholism
por: Singhania, Girish, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
por: Cahova, Monika, et al.
Publicado: (2021)

The Yin and Yang of the Renin–Angiotensin–Aldosterone System in Acute Kidney Injury
por: Legrand, Matthieu, et al.
Publicado: (2021)

Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients
por: Vejakama, Phisitt, et al.
Publicado: (2017)

Hydrogen Sulfide Attenuates Renin Angiotensin and Aldosterone Pathological Signaling to Preserve Kidney Function and Improve Exercise Tolerance in Heart Failure
por: Li, Zhen, et al.
Publicado: (2018)

Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
por: Ferrari, Filipe, et al.
Publicado: (2021)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Static pressures, intra-access blood flow and dynamic Kt/V profiles in the prediction of dialysis access function
por: Koratala, Abhilash, et al.
Publicado: (2019)

Prevalence of aldosterone breakthrough in dogs receiving renin‐angiotensin system inhibitors for proteinuric chronic kidney disease
por: Ames, Marisa K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nl3g5ceq4kgml7m1kidenmj196